child with genetic confirmation of dravet syndrome a documented sodium channel voltage-gated type i alpha subunit scn1a mutation or clinical confirmation of dravet syndrome by two pediatric neurologist will be consider to have dravet syndrome in order to enter the treatment protocol there will be document treatment failure of at least two therapeutic anticonvulsant exclude na channel blocker anticonvulsant that be na channel blocker such a carbamazepine and lamotrigine a know to provoke seizure in this patient population 